ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient

Recognizing superior service, support, reliability, ethics and integrity

Fresenius Kabi has been named the 2022 Pharmaceutical Supplier Partner of the Year by Vizient, Inc., the nation’s largest member-driven health care performance improvement company. The recognition was September 19-21 at the 2022 Vizient Connections Summit in Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221006005071/en/

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient (Graphic: Business Wire)

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient (Graphic: Business Wire)

The Pharmaceutical Supplier Partner of the Year award recognizes suppliers for their superior service, support, reliability, ethics and integrity. This year, Vizient recognized Fresenius Kabi for providing comprehensive contract access and proactively engaging the broader Vizient enterprise, including consulting and Pharmacy Networks, in support of Vizient pharmacy members.

“We are honored to receive the 2022 Pharmaceutical Supplier Partner of the Year award from Vizient. Customer focus is one of our company values and everyone at Fresenius Kabi plays a critical role in supporting Vizient, its members and the patients they serve. This recognition is a testament to the dedication and care our employees demonstrate, regardless of their individual roles,” said Scott Meacham, president, Pharmaceuticals at Fresenius Kabi USA.

Since 2016, Fresenius Kabi has been named the Vizient Pharmaceutical Supplier Partner of the Year three times, received the overall Supplier of the Year award, and was recognized twice as the Vizient Strategic Programs Pharmaceutical Supplier of the Year.

“We are pleased to recognize Fresenius Kabi as this year’s winner of the Pharmaceutical Supplier Partner of the Year award. Their commitment to product quality and to delivering the highest level of service to our members is exemplary. It is evident that the needs of hospitals and patients are at the center of their market strategy,” said Bharat Sundaram, president and chief operating officer for Vizient.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at http://www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.